Suzie Cro, Tim P. Morris, James H. Roger, James R. Carpenter
{"title":"关于 \"基于标准和参照的条件均值估算 \"的评论:监管者和试验统计人员须知!","authors":"Suzie Cro, Tim P. Morris, James H. Roger, James R. Carpenter","doi":"10.1002/pst.2373","DOIUrl":null,"url":null,"abstract":"Accurate frequentist performance of a method is desirable in confirmatory clinical trials, but is not sufficient on its own to justify the use of a missing data method. Reference‐based <jats:italic>conditional mean</jats:italic> imputation, with variance estimation justified solely by its frequentist performance, has the surprising and undesirable property that the estimated variance becomes smaller the greater the number of missing observations; as explained under jump‐to‐reference it effectively forces the true treatment effect to be <jats:italic>exactly</jats:italic> zero for patients with missing data.","PeriodicalId":19934,"journal":{"name":"Pharmaceutical Statistics","volume":"107 1","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comments on ‘standard and reference‐based conditional mean imputation’: Regulators and trial statisticians be aware!\",\"authors\":\"Suzie Cro, Tim P. Morris, James H. Roger, James R. Carpenter\",\"doi\":\"10.1002/pst.2373\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Accurate frequentist performance of a method is desirable in confirmatory clinical trials, but is not sufficient on its own to justify the use of a missing data method. Reference‐based <jats:italic>conditional mean</jats:italic> imputation, with variance estimation justified solely by its frequentist performance, has the surprising and undesirable property that the estimated variance becomes smaller the greater the number of missing observations; as explained under jump‐to‐reference it effectively forces the true treatment effect to be <jats:italic>exactly</jats:italic> zero for patients with missing data.\",\"PeriodicalId\":19934,\"journal\":{\"name\":\"Pharmaceutical Statistics\",\"volume\":\"107 1\",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pst.2373\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pst.2373","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Comments on ‘standard and reference‐based conditional mean imputation’: Regulators and trial statisticians be aware!
Accurate frequentist performance of a method is desirable in confirmatory clinical trials, but is not sufficient on its own to justify the use of a missing data method. Reference‐based conditional mean imputation, with variance estimation justified solely by its frequentist performance, has the surprising and undesirable property that the estimated variance becomes smaller the greater the number of missing observations; as explained under jump‐to‐reference it effectively forces the true treatment effect to be exactly zero for patients with missing data.
期刊介绍:
Pharmaceutical Statistics is an industry-led initiative, tackling real problems in statistical applications. The Journal publishes papers that share experiences in the practical application of statistics within the pharmaceutical industry. It covers all aspects of pharmaceutical statistical applications from discovery, through pre-clinical development, clinical development, post-marketing surveillance, consumer health, production, epidemiology, and health economics.
The Journal is both international and multidisciplinary. It includes high quality practical papers, case studies and review papers.